Julia Finkel
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Julia Finkel sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Julia Finkel: 7 sponsored US clinical trials, 1 recruiting.
Julia Finkel sponsors 7 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 5 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Analgesics, Antipyretics and Anti-Inflammatory Drugs Causing Adverse Effects in Therapeutic Use, with 1 trials.
Upper-quartile sponsor footprint
Julia Finkel sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
Measuring Analgesic Interventions
NCT03794362
Developing a Method to Objectively Measure Opioid Analgesia
NCT03605966
Objective Assessment of Sensory Nerve Fiber Sensitivity
NCT03596489
SCD-PROMIS: A Software Platform to Enhance Self-efficacy and Patient-provider Engagement for Patients With Sickle Cell Pain
NCT03006718
Objective Measurement of Pain Using the Algometer
NCT02325284
QST-Pupillometry in Sickle Cell Disease Patients
NCT02242058
Low Dose Ketamine Study on Opioid Tolerance and Hyperalgesia
NCT01325493
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 4 | 1 |
Where Julia Finkel enrollment is open (later-stage tilt)
1 recruiting of 7 indexed (14% open); 5 completed (71%).
Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Analgesics, Antipyretics and Anti-Inflammatory Drugs Causing Adverse Effects in Therapeutic Use (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Julia Finkel: open-pipeline peers nationwide
Peers matched on 7 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Julia Finkel sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Academic and Community Cancer Research United · 14% recruiting · 42 trials
- Adaptive Biotechnologies · 14% recruiting · 7 trials
- AgelessRx · 14% recruiting · 7 trials
- Alaska Blind Child Discovery · 14% recruiting · 7 trials
Related
What to do with this Julia Finkel page
7 registered trials is a research-attention snapshot, not an endorsement of Julia Finkel or any single study.
- 1 of Julia Finkel's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Analgesics, Antipyretics and Anti-Inflammatory Drugs Causing Adverse Effects in Therapeutic Use is the condition Julia Finkel studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Analgesics, Antipyretics and Anti-Inflammatory Drugs Causing Adverse Effects in Therapeutic Use trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Julia Finkel pipeline card: 7 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.